Identifying and Characterizing HIV Protease Inhibitors.

Area of Science:

• Biochemistry
• Virology
• Medicinal Chemistry

Background:

• HIV protease is essential for viral replication, making it a key target for antiretroviral therapy.
• Approved HIV protease inhibitors like saquinavir, ritonavir, indinavir, and nelfinavir have shown efficacy but face challenges.
• Viral resistance and complex dosing regimens limit the long-term effectiveness of current HIV protease inhibitors.

Purpose of the Study:

• To highlight the ongoing need for novel HIV protease inhibitors.
• To emphasize the limitations of existing therapies, including drug resistance and adherence issues.
• To underscore the importance of developing inhibitors with distinct resistance profiles.

Main Methods:

• Review of existing literature on HIV protease inhibitors.
• Analysis of clinical trial data for approved and investigational drugs.
• Assessment of mechanisms of viral resistance to protease inhibitors.

Main Results:

• Several HIV protease inhibitors are approved and in clinical trials, demonstrating therapeutic potential.
• Challenges remain, including difficulties with patient adherence to dosing schedules.
• In vivo development of resistance to individual and multiple protease inhibitors is a significant clinical problem.

Conclusions:

• Despite successes, a critical need persists for new HIV protease inhibitors.
• Novel inhibitors must address current limitations, particularly regarding resistance development.
• Developing agents with alternative resistance profiles is essential for advancing HIV treatment.